Mostrar o rexistro simple do ítem

dc.contributor.advisorLópez López, Rafael
dc.contributor.advisorAbdulkader, Ihab
dc.contributor.advisorMuinelo Romay, Laura
dc.contributor.authorLeón Mateos, Luis
dc.date.accessioned2019-02-25T11:29:28Z
dc.date.available2019-02-25T11:29:28Z
dc.date.issued2016
dc.identifier.urihttp://hdl.handle.net/10347/18299
dc.description.abstractBackground. Prostate cancer (PCa) is the most common diagnosed male malignancy in the Western world. One third of patients will develop metastatic castration resistant prostate cancer (mCRPC). To monitor systemic disease, the study of circulating tumor cells (CTCs) can be a supplement or an alternative to the serum PSA and imaging methods. In the present study we assessed the value of CTC count and molecular characterization to manage mCRPC patients. Methods. Blood samples from 29 mCRPC patients treated with first line taxanes were analyzed at four different time points. Samples were first processed by the Cellsearch platform. Besides we did a CTC isolation and a gene expresson analysis by RT-qPCR at baseline in 29 mCPRC. In addition a whole gene expression analysis was carried out on blood samples extracted from 9 patients and from 6 healthy donors. Results. CTC count worked as a prognostic factor: median OS was 16 months for those patients with ≥5 CTCs at baseline versus not reached for those < 5 CTCs. In addition to the CTC count we identified a molecular CTCs-signature that could be useful for the initial diagnosis, prognosis and therapy monitoring. Thus, high levels of AR, CYP19 and GDF15 were associated with poor PFS rates while AR, GDF15 and BIRC5 were also found as consistent predictors of OS in the univariate analysis. Finally after the global gene expression approach we found a general stress-survival phenotype in the CTC population of mCRPC patients partially based on cell proliferation, apoptosis, adhesion and migration. Conclusions. In our cohort CTC count using CellSearch technology has prognostic value. In parallel, we have also demonstrated the feasibility of an alternative method of CTC isolation and gene expression analysis, identifying a panel of genes with prognostic relationship and deserves to be explored for the treatment monitoring.
dc.language.isoeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCirculating tumor cells
dc.subjectCTC
dc.subjectcastration resistant prostate cancer
dc.subjectglobal gene expression analysis
dc.subject.classificationMaterias::Investigación::32 Ciencias médicas::3201 Ciencias clínicas::320101 Oncología
dc.subject.classificationMaterias::Investigación::32 Ciencias médicas::3207 Patología::320713 Oncología
dc.titleClinical application of circulating tumor cells in patients with metastatic castration-resistant prostate cancer
dc.typedoctoral thesis
dc.rights.accessRightsopen access
dc.contributor.affiliationUniversidade de Santiago de Compostela. Facultade de Medicina e Odontoloxía
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina


Ficheiros no ítem

application/pdf
Nome: rep_1754
Tamaño: 33.60 Mb
Formato: PDF


Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
A licenza do ítem descríbese como
 Attribution-NonCommercial-NoDerivatives 4.0 Internacional





Recolectores:Enlaces de interese:
Universidade de Santiago de Compostela | Teléfonos: +34 881 811 000 e +34 982 820 000 | Contacto | Suxestións